Table 1.
Clinical and molecular characteristics of patients included in the ovarian cancer cohort of the PERMED-01 trial.
| Number of patients | 24 |
|---|---|
| Median age (years, range) | 54.3 [21.7–71.1] |
| Histology | |
| - HGSC - LGSC - Clear cell - Endometrioid - Carcinosarcoma |
16 3 3 1 1 |
| Site of baseline biopsy | |
| - Peritoneum - Lymph nodes - Liver - other |
9 (38%) 7 (29%) 6 (25%) 2 (8%) |
| Platinum-resistant at inclusion | 22 (92%) |
| Priori lines of chemotherapy | |
| - Median (range) | 3 (1-6) |
| Most frequent somatic alterations | |
| - TP53 mutation - ARID1A mutation - ARID1A loss - PI3KCA mutation |
15 (63%), Including 15/16 HGSC (92%) 2 (8%, all clear cell) 2 (8%, all LGSC) 2 (8%, 1 clear cell, 1 endometrioid) |
| Actionable genetic alterations | 10 (42%) |
| Genomic-guided therapies | 3 (13%) |
| - Lapatinib - Sorafenib - Everolimus |
ERBB2 amp, PD KRAS mut, SD PIK3CA mut, PR |
Data are expressed as N (%) unless otherwise specified. HGSC, high-grade serous cancer; LGSC, low-grade serous cancer; PD, progressive disease; SD, stable disease; PR, partial response.